Autor según el artículo: Cano A; Ettcheto M; Espina M; Auladell C; Folch J; Kühne BA; Barenys M; Sánchez-López E; Souto EB; García ML; Turowski P; Camins A
Departamento: Bioquímica i Biotecnologia
Autor/es de la URV: Folch Lopez, Jaume
Palabras clave: Polymeric nanoparticles Plga-peg Neurodegenerative diseases Huntington's disease Epigallocatechin-3-gallate 3-nitropropionic acid
Resumen: © 2021 Future Medicine Ltd. Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntington's disease (HD)-like symptoms in mice. Materials & methods: EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal lesions and motor deficit were induced in mice by 3-nitropropionic acid-intoxication. EGCG and EGCG/AA NPs were co-administered and behavioral motor assessments and striatal histology performed after 5 days. Results: EGCG/AA NPs were significantly more effective than free EGCG in reducing motor disturbances and depression-like behavior associated with 3-nitropropionic acid toxicity. EGCG/AA NPs treatment also mitigated neuroinflammation and prevented neuronal loss. Conclusion: NP encapsulation enhances therapeutic robustness of EGCG in this model of HD symptomatology. Together with our previous findings, this highlights the potential of EGCG/AA NPs in the symptomatic treatment of neurodegenerative diseases.
Áreas temáticas: Química Nanoscience and nanotechnology Nanoscience & nanotechnology Medicine (miscellaneous) Medicina ii Materials science (miscellaneous) Materials science (all) Materiais Interdisciplinar General medicine General materials science Farmacia Engenharias ii Economia Development Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência da computação Biotecnología Biotechnology & applied microbiology Biomedical engineering Bioengineering Biodiversidade Astronomia / física
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: jaume.folch@urv.cat
Identificador del autor: 0000-0002-5051-8858
Fecha de alta del registro: 2024-07-27
Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
Enlace a la fuente original: https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2020-0239
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Nanomedicine. 16 (1): 19-35
Referencia de l'ítem segons les normes APA: Cano A; Ettcheto M; Espina M; Auladell C; Folch J; Kühne BA; Barenys M; Sánchez-López E; Souto EB; García ML; Turowski P; Camins A (2021). Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. Nanomedicine, 16(1), 19-35. DOI: 10.2217/nnm-2020-0239
DOI del artículo: 10.2217/nnm-2020-0239
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2021
Tipo de publicación: Journal Publications
Repositori URV